Skip to main content

Conmed Value Stock - Dividend - Research Selection

Conmed

ISIN: US2074101013 , WKN: 886793

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician\'s office electrosurgical product used by dermatologists. The company\'s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


B of A Securities Maintains Neutral on Conmed, Lowers Price Target to $40

2026-05-18
B of A Securities analyst Travis Steed maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $52 to $40.

Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $39

2026-05-01
Wells Fargo analyst Larry Biegelsen maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $42 to $39.

JP Morgan Maintains Neutral on Conmed, Lowers Price Target to $40

2026-04-30
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $43 to $40.

An undisclosed buyer acquired remaining GI product lines of CONMED Corporation.

2026-04-30
An undisclosed buyer signed an agreement to acquire remaining GI product lines of CONMED Corporation in April 2026. An undisclosed buyer completed the acquisition of remaining GI product lines of...

CONMED Corporation 2026 Q1 - Results - Earnings Call Presentation

2026-04-30
2026-04-30. The following slide deck was published by CONMED Corporation in conjunction with their 2026 Q1 earnings call.

Transcript : CONMED Corporation, Q1 2026 Earnings Call, Apr 29, 2026

2026-04-30
Presentation Operator MessageOperator Good day and thank you for standing by. Welcome to CONMED's First Quarter Fiscal 2026 Earnings Conference Call. [Operator Instructions] Please be advised that...

CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript

2026-04-30
CONMED Corporation (CNMD) Q1 2026 Earnings Call April 29, 2026 4:30 PM EDTCompany ParticipantsPatrick Beyer - President, CEO & DirectorTodd Garner -...

CONMED Corporation (NYSE:CNMD) Beats Q1 Estimates and Raises Revenue Guidance, Shares Steady

2026-04-29
CONMED beats Q1 estimates with adjusted EPS of $0.89, slightly tops revenue forecasts, and raises full-year organic revenue guidance despite a strategic product exit.

Conmed Raises FY2026 Sales Guidance from $1.345B-$1.375B to $1.350B-$1.375B vs $1.359B Est

2026-04-29
Conmed (NYSE:CNMD) raises FY2026 sales outlook from $1.345 billion-$1.375 billion to $1.350 billion-$1.375 billion vs $1.359 billion estimate.

Conmed Q1 Adj. EPS $0.89 Beats $0.82 Estimate, Sales $317.046M Beat $310.507M Estimate

2026-04-29
Conmed (NYSE:CNMD) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.82 by 8.54 percent. This is a 6.32 percent decrease over earnings of $0.95 per share from the same period